Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Divergent TIR signaling domains in TLR7 and TLR9 control opposing effects on systemic autoimmunity
Claire Leibler, Kayla B. Thomas, Coralie Josensi, Russell C. Levack, Shuchi Smita, Shinu John, Daniel J. Wikenheiser, Sheldon Bastacky, Sebastien Gingras, Kevin M. Nickerson, Mark J. Shlomchik
Claire Leibler, Kayla B. Thomas, Coralie Josensi, Russell C. Levack, Shuchi Smita, Shinu John, Daniel J. Wikenheiser, Sheldon Bastacky, Sebastien Gingras, Kevin M. Nickerson, Mark J. Shlomchik
View: Text | PDF
Research Article Autoimmunity Immunology

Divergent TIR signaling domains in TLR7 and TLR9 control opposing effects on systemic autoimmunity

  • Text
  • PDF
Abstract

Toll like receptor (TLR) 7 and 9, endosomal sensors for RNA and DNA, are key mediators of autoreactivity. Although generally considered homologous, they paradoxically have opposing effects on lupus: TLR7 exacerbates the disease while TLR9 protects from it How they mediate opposing effects in autoimmunity remains undetermined. We hypothesized that differences in signaling qualities of the Toll-Interleukin 1 Receptor (TIR) domains of TLR7 and TLR9 could be responsible for their opposing effects. To test this, we introduced the TIR domain of TLR9 into the endogenous Tlr7 locus and the TLR7 TIR domain into the endogenous Tlr9 locus of mice, creating chimeric molecules termed TLR779 and TLR997. Lupus-prone MRL/lpr mice carrying Tlr779 had greatly ameliorated disease, while MRL/lpr mice carrying Tlr997 had markedly exacerbated disease compared with respective TlrWT mice. These experiments establish that TLR7 and TLR9 TIR domains have divergent properties and control disease quality, thus explaining the longstanding “TLR paradox”.

Authors

Claire Leibler, Kayla B. Thomas, Coralie Josensi, Russell C. Levack, Shuchi Smita, Shinu John, Daniel J. Wikenheiser, Sheldon Bastacky, Sebastien Gingras, Kevin M. Nickerson, Mark J. Shlomchik

×

Figure 2

Differences in B cell–signaling qualities driven by TLR777 or TLR779.

Options: View larger image (or click on image) Download as PowerPoint
Differences in B cell–signaling qualities driven by TLR777 or TLR779.
Tr...
Transcriptome analysis of bead-purified B cells from 5–7week-old Tlr7+/Y Tlr9–/– or Tlr779/Y Tlr9–/– male MRL/lpr mice that were stimulated with TLR7 agonist (CL097; 5 μg/ml) for 4 hours. (A) Number of differentially expressed genes (DEGs) identified using the limma R package (log2 FC > 0.5 and FDR-corrected P < 0.05), between stimulated versus unstimulated samples (first 2 columns) or between the 2 genotypes, with or without stimulation (last 2 columns). (B) Upstream regulators that are predicted to be significantly activated upon CL097 stimulation by the IPA software in Tlr7+/Y (Y-axis) or Tlr779/Y (X-axis) B cells. XY plot shows the predicted z-score. (C) Bubble plot shows the top 15 reactome pathways enriched in Tlr779/Y (stim) (pink bubbles) and Tlr7+/Y (stim) (dark blue bubbles) regulated genes (from the Tlr779/Y (stim) vs Tlr7+/Y (stim) comparison). X-axis shows the –log10 FDR for the enriched terms displayed on Y-axis. Bubble size shows the genes in the pathway that are also differentially expressed in Tlr779/Y versus Tlr7+/Y. Enrichment was calculated using Fisher’s exact test (with all expressed genes as background) followed by Storey’s Q value FDR correction. (D) Volcano plot representing the DEGs between Tlr7+/Y and Tlr779/Y stimulated B cells. X-axis shows the log2 fold change value and Y-axis shows –log10 (FDR). The dotted lines separate the significant (FDR < 0.05) and nonsignificant (FDR > 0.05) genes and indicate the log2FC –0.5 and 0.5 cut-offs. The significant DEGs (log2 FC > 0.5, and FDR-corrected P value of < 0.05) were annotated based on the reported functions of their corresponding proteins in B cell activation (green dots), cell death (yellow dots), TLR-mediated inflammation (red dots), negative regulation of TLR-mediated inflammation and cell activation (blue dots), or if the genes were IFN-induced genes (pink dots).

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts